Otonomy, Inc. (OTIC)

NASDAQ: OTIC · IEX Real-Time Price · USD
0.118
+0.009 (8.35%)
Feb 3, 2023, 3:56 PM EST - Market closed
8.35%
Market Cap 6.75M
Revenue (ttm) n/a
Net Income (ttm) -52.26M
Shares Out 57.15M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,077,162
Open 0.112
Previous Close 0.109
Day's Range 0.108 - 0.123
52-Week Range 0.060 - 2.590
Beta 1.46
Analysts Buy
Price Target 9.18 (+7,673.07%)
Earnings Date Feb 27, 2023

About OTIC

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the pr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2014
Employees 51
Stock Exchange NASDAQ
Ticker Symbol OTIC
Full Company Profile

Financial Performance

In 2021, Otonomy's revenue was $125,000, a decrease of -54.21% compared to the previous year's $273,000. Losses were -$51.18 million, 14.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OTIC stock is "Buy." The 12-month stock price forecast is $9.18, which is an increase of 7,673.07% from the latest price.

Price Target
$9.18
(7,673.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Otonomy Announces Change in Stock Exchange Listing

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indica...

1 month ago - GlobeNewsWire

Otonomy Provides Corporate Update

SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of...

1 month ago - GlobeNewsWire

5 Investors Betting Big on Otonomy (OTIC) Stock

Shares of Otonomy (NASDAQ: OTIC) stock are in the spotlight again today. Although it's in the red today, OTIC stock sports a five-day gain of more than 100%.

2 months ago - InvestorPlace

Why Is Otonomy (OTIC) Stock Up 97% Today?

Otonomy (NASDAQ: OTIC) stock is on the move Tuesday despite a lack of news from the biopharmaceutical company. Instead, it looks like traders have latched onto OTIC stock as the next big short squeez...

2 months ago - InvestorPlace

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the...

4 months ago - GlobeNewsWire

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the...

6 months ago - GlobeNewsWire

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

6 months ago - GlobeNewsWire

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will ...

7 months ago - GlobeNewsWire

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...

9 months ago - GlobeNewsWire

Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...

9 months ago - GlobeNewsWire

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

9 months ago - GlobeNewsWire

Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will r...

9 months ago - GlobeNewsWire

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positiv...

10 months ago - GlobeNewsWire

Otonomy to Host Virtual Investor R&D Event on March 22, 2022

SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it...

11 months ago - GlobeNewsWire

Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

1 year ago - GlobeNewsWire

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that man...

1 year ago - GlobeNewsWire

Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the comp...

1 year ago - GlobeNewsWire

Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will ...

1 year ago - GlobeNewsWire

Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upc...

1 year ago - GlobeNewsWire

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple...

1 year ago - GlobeNewsWire

Otonomy Reports Corporate and Product Pipeline Update

Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss  expected during 2022

1 year ago - GlobeNewsWire

Otonomy to Participate in the H.C. Wainwright BioConnect Conference

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its part...

1 year ago - GlobeNewsWire

Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its part...

1 year ago - GlobeNewsWire

Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

1 year ago - GlobeNewsWire